Search Results
Your search for ,OUr matches 10645 pages
Showing 101 - 150SCLC: Small Study Tests Efficacy of CTCs in Predicting Response to Tarlatamab
A research team has discovered that a particular marker on circulating tumor cells (CTCs) may indicate whether a patient with small cell lung cancer (SCLC) will experience a lasting response to tarlatamab-dlle, a newly approved immunotherapy. The findings, which were published by Mishra in Cancer...
Improved Contralateral Breast Cancer Risk Knowledge With Personalized Counseling Tool
Patients with unilateral breast cancer who underwent quantitative counseling with a personalized tool incorporating genetic testing results were better informed of their contralateral breast cancer risk compared with those who received standard counseling, according to results from the GET FACTS...
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
A deep learning model demonstrated the ability to predict breast cancer recurrence risk and possible benefit from the addition of chemotherapy based on histopathologic images rather than genomic testing in patients with hormone receptor–positive, HER2-negative breast cancer, according to findings...
Multiple Myeloma: Sex Differences in Etiology and Clinical Presentation
Rates of multiple myeloma, the second most common blood cancer in the United States, are increasing and are twice as high in men than in women. A new study published by Ong et al in the journal Cancer provides insights that may help to explain this disparity. To investigate the sex difference in...
FDA Increases Flexibility on Requirements for Cell and Gene Therapies
The U.S. Food and Drug Administration (FDA) has announced it is sharing information about the agency’s flexible approach to overseeing chemistry, manufacturing, and control (CMC) requirements for cell and gene therapies (CGTs). The agency’s more flexible approach has been, and is expected to...
MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma
For patients with previously treated multiple myeloma, the greatest risk reduction yet achieved in a phase III clinical trial was reported with the BCMA-directed CD3 T-cell engager teclistamab-cqyv plus daratumumab and hyaluronidase-fihj. Treatment with this combination resulted in an 83% reduction ...
Refractory LBCL: CD19-Targeting CAR T-Cell Therapy Plus Rituximab
A dual-antigen targeting combination of the CD19-targeting chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel plus the CD20-targeting agent rituximab led to durable responses and reduced relapses in patients with refractory large B-cell lymphoma (LBCL), according to findings...
Can KDM6A Mutations Help Guide Treatment Selection in Bladder Cancer?
Mutations in KDM6A have been identified as a regulator of therapeutic responses in advanced bladder cancer, sensitizing tumors to anti–PD-1 immune checkpoint inhibition but resisting cisplatin chemotherapy, according to early research published in Nature Communications. Based on this and further...
In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL
Based on the phase III CLL17 trial, a fixed duration of targeted treatment demonstrated noninferiority to continuous treatment with respect to progression-free survival in previously untreated patients with chronic lymphocytic leukemia (CLL). The findings were presented at the Plenary Session of...
Researchers Create Immune Cell Atlas of Bone Marrow in Patients With Multiple Myeloma
Scientists at several institutions across the country, in partnership with the Multiple Myeloma Research Foundation (MMRF), have helped generate the largest single-cell immune cell atlas of the bone marrow in patients with multiple myeloma. The findings, published by Pilcher et al in Nature Cancer, ...
Small Study Examines Potential of Artificial Saliva in Patients With Head and Neck Cancer
An artificial saliva in the form of a mouthwash, produced with a protein extracted from sugarcane and modified in a laboratory, may aid in treating hyposalivation among patients with head and neck cancer, a new study has found. Radiotherapy delivered very close to the mouth can destroy salivary...
Investigational PSMA-Targeted Radioligand Reduced Off-Target Uptake in Prostate Cancer Models
A novel prostate-specific membrane antigen (PSMA)-targeted radioligand therapy shows the potential to enhance therapeutic effects for patients with PSMA-positive prostate cancer while eliminating the potential for severe adverse effects such as xerostomia, according to preclinical findings...
Benefit of Azacitidine Plus Venetoclax Confirmed in AML
The combination of the hypomethylating agent azacitidine and the BCL2 inhibitor venetoclax is an established regimen in older, unfit patients with acute myeloid leukemia (AML). Now, a phase II randomized trial indicates potential for less intensive therapy in the newly diagnosed fit population. In...
ACS Guidelines for Cervical Cancer
Self-collection of vaginal samples for human papillomavirus (HPV) testing is now being considered an acceptable, recommended option for cervical cancer screening, per recent updates to the American Cancer Society’s (ACS) guidelines published in CA: A Cancer Journal for Clinicians. Another...
Using AI to Ensure That All Patients With Cancer Have Access to Precision Oncology Care
Steve Brown, Founder and Chief Executive Officer of CureWise (curewise.com), an artificial intelligence (AI)-driven patient advocacy app, describes his year-long quest to understand a series of symptoms that ultimately led to a diagnosis of light chain (AL) amyloidosis—a disease closely related to ...
Study Finds GLP-1 RAs May Influence Colorectal Cancer Mortality
Colon cancer is among the leading causes of cancer-related morbidity and mortality both in the United States and globally. Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may influence cancer mortality, and the results from a new study may add to that mounting ...
AI-Based Imaging Model Predicts Extranodal Extension Burden and Improves Risk Stratification in Oropharyngeal Cancer
Prediction of the number of lymph nodes with extranodal extension in patients with oropharyngeal carcinoma through a deep learning imaging platform for autosegmentation may help to guide pretreatment patient risk stratification and treatment decision-making, according to the results of a multisite, ...
ASTRO Relaunches Research Foundation Under a Single, Focused Identity
The American Society of Radiation Oncology (ASTRO) has announced that they have rebranded their research foundation from the former Radiation Oncology Institute (ROI) to become Speed of Light – The ASTRO Foundation. The intent of the renamed research foundation was to bring both ASTRO and the...
A Novel Paradigm in Acute Kidney Injury: Congestive Nephropathy in RCC With IVC Thrombus
Researchers have proposed a new mechanism of acute kidney injury to account for patients with renal cell carcinoma (RCC) who have an inferior vena cava (IVC) tumor thrombus, according to findings presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO).1 By analyzing...
Deb Schrag, MD, MPH, FASCO, Elected 2027–2028 ASCO President
On December 19, 2025, ASCO announced its members had elected Deb Schrag, MD, MPH, FASCO, as President for the 2027–2028 term. Dr. Schrag will begin her term as President-Elect following the conclusion of the 2026 ASCO Annual Meeting. Dr. Schrag, a gastrointestinal medical oncologist, is the George ...
Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns
Researchers have uncovered that sex-specific dysregulation of exosomal non-coding RNAs may drive different patterns of disease progression of multiple myeloma in male and female individuals, according to findings published in Blood Cancer Journal. “The same therapies are provided for men and women ...
NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer
Circulating tumor DNA (ctDNA) levels may help to determine which patients with colon cancer could benefit from the addition of nonsteroidal anti-inflammatory drugs (NSAIDs), such as celecoxib, to chemotherapy following surgery, according to findings from a post hoc analysis of the CALGB/SWOG 80702...
Community Oncology Report Showcases Barriers to Therapy Access, Staffing, and Clinical Trial Participation
A report recently released by McKesson on the state of community oncology highlights the current challenges facing physicians, administrators, and clinical staff who work in community practices. The "Advancing Community Oncology Report" details these challenges as well as opportunities for growth...
Flipped Nivolumab/Ipilimumab Dosing Improves Responses, Survival, and Safety in Advanced Melanoma
The flipped dose for nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg led to improved response rates and survival findings as well as lower severe immune-related toxicities compared with the standard dose of the immunotherapy combination in patients with advanced unresectable melanoma, according to...
AI Models Advance Individualized Breast Cancer Recurrence Risk Assessments
Two presentations at the 2025 San Antonio Breast Cancer Symposium (SABCS) highlighted new artificial intelligence (AI) tools and systems for improving distant recurrence risk stratification among patients with early-stage breast cancer. The first tested multimodal AI models with imaging, clinical,...
Is Menopausal Hormone Therapy Associated With Increased Breast Cancer Risk?
Using menopausal hormone therapy was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results of a matched prospective analysis presented at the 2025 San Antonio Breast Cancer Symposium (SABCS; Abstract GS3-01)....
Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer?
Multimodal artificial intelligence (AI) models using a combination of molecular, imaging, and clinical features improved the individual prognostic assessment of patients with early breast cancer's risk of distant recurrence, according to an analysis presented at the 2025 San Antonio Breast Cancer...
Sacituzumab Govitecan vs Standard of Care for Certain Endocrine Therapy–Refractory Advanced Breast Cancers
Patients with hormone receptor–positive, HER2-negative advanced breast cancers had similar progression-free survival whether they were treated with sacituzumab govitecan-hziy or standard-of-care chemotherapy as the first treatment after endocrine therapy, according to results from the phase III...
Phase III Trial Shows No Oncologic Benefit From Routine Preoperative MRI for Some Early Breast Cancers
Rates of local regional recurrence were very low for patients with early-stage triple-negative or HER2-positive breast cancer regardless of whether or not they received a breast MRI for staging and surgical planning, according to findings from the phase III Alliance A011104/ACRIN 6694 trial...
HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer
The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patients with HER2-positive metastatic breast cancer, according to findings presented at the 2025 San...
Abbreviated Azacitidine Regimen Improves Outcomes in Lower-Risk MDS
A multicenter trial led by investigators at The University of Texas MD Anderson Cancer Center demonstrated that a 5-day regimen of azacitidine provides the best balance of efficacy and safety for patients with lower-risk myelodysplastic syndromes (MDS). The researchers compared three abbreviated...
AI Tops Density in Predicting Breast Cancer Risk
An image-only artificial intelligence (AI) model for predicting the 5-year risk of breast cancer provided stronger and more precise risk stratification than breast density assessment, according to a news statement issued about a study presented at the annual meeting of the Radiological Society of...
Hear, Hear to ‘Advancing Geriatric Oncology: Where We Have Been and Where We Are Going’
We read with interest the commentary by Stuart Lichtman, MD, FASCO,on “Advancing Geriatric Oncology: Where We Have Been and Where We Are Going,“ in the October 25, 2025 issue of The ASCO Post.1 Dr. Lichtman outlines the challenges in delivering cancer care to the elderly population. Among these...
Christine M. Lovly, MD, PhD, FASCO, Named Head, Thoracic Oncology, at City of Hope
Christine M. Lovly, MD, PhD, FASCO, an expert on lung cancer with almost 2 decades of experience in clinical care, translational research, and academic leadership, will spearhead the new national thoracic oncology program at City of Hope in Duarte, California. In her new role, effective January 1, ...
Doublet Therapy Yields Higher Response Rates and Fewer Complications Than Standard Induction in AML
The combination of azacitidine and venetoclax led to improved efficacy outcomes with fewer complications than standard intensive induction chemotherapy as upfront treatment for patients with acute myeloid leukemia (AML), according to trial findings presented at the 2025 American Society of...
Integrating Mental Health Into Cancer Care: A Community Oncology Imperative
When Julie began chemotherapy for breast cancer, her oncologist adjusted antiemetics weekly and carefully tracked neutrophil counts. Still, no one asked about the panic attacks that kept her awake at night. She told herself this was just part of cancer. It was not until she stopped showing up for...
High Risk of Metastatic Recurrence Among Young Patients With Cancer
A new study of adolescents and young adults (AYAs) with seven common cancers reveals that nearly one in ten patients diagnosed with non-metastatic disease later develop metastatic recurrence. The information was shared in a news statement from the UC Davis Comprehensive Cancer Center. Scientists at ...
The Diagnosis I Couldn’t Deliver: An Oncologist’s Journey Between Roles
As a medical oncologist and palliative care physician, I have spent years preparing for difficult conversations. I’ve guided patients and families through the uncertainty of cancer, helped them navigate complex decisions, and sought meaning amid shifting prognoses. As an academic, I teach future...
Mount Sinai Tisch Cancer Center Receives Comprehensive Cancer Center Designation and Funding from National Cancer Institute
The Mount Sinai Tisch Cancer Center (TCC) has been named a Comprehensive Cancer Center by the National Cancer Institute (NCI), the highest designation awarded to cancer centers in the United States. This recognition places Mount Sinai among the top one percent of cancer centers nationwide and...
Eliminating Barriers to Care for Patients With Intellectual and/or Developmental Disabilities
A recent large, retrospective study by Giblon et al has found that individuals with intellectual and/or developmental disabilities face an increased risk of developing cancer, higher symptom burden once they get cancer compared with those without such disabilities, and disparities in accessing...
Montefiore Einstein Comprehensive Cancer Center Director, Physician Scientist, Edward Chu, MD, MMS, Dies at 66
Albert Einstein Collegeof Medicine and Montefiore Einstein Comprehensive Cancer Center shared news of the death of the Cancer Center’s Director, Edward Chu, MD, MMS, on November 13, 2025. The cause of death was glioma. Here is the statement: “We are deeply saddened to share the news that Dr. Ed...
One in Three Families of Children With ALL Face Financial Hardship During Treatment
A new multicenter study reports that nearly one-third of families with children undergoing chemotherapy for acute lymphoblastic leukemia (ALL) develop substantial financial hardships during the 2 years of treatment. These difficulties—defined as the inability to pay for housing, food, or utilities, ...
How AI Is Ushering in a New Era in Cancer Care
On October 30, 2025, Google Cloud held its second annual Cancer AI Symposium to explore how artificial intelligence (AI) is advancing cancer research, diagnosis, and treatment, in unparalleled ways. Held at Google’s St. John’s Terminal office in New York City, the event brought together leaders in...
Ross Levine, MD, Named Chief Scientific Officer of Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSK) announced that Ross Levine, MD, has been named MSK’s new Chief Scientific Officer (CSO). Dr. Levine previously served as Senior Vice President of Translational Research in Memorial Hospital (MH) and holds the Edward P. Evans Endowed Chair for...
Non–Total Body Irradiation Conditioning Regimen for Young Patients With MRD-Negative B-ALL
Two-year event-free survival rates were above 75% for children, adolescent, and young adult patients with B-cell acute lymphocytic leukemia (B-ALL) who had negative measurable residual disease (MRD) by next-generation sequencing prior to hematopoietic cell transplantation and who received a...
Building the Cancer Care Africa Deserves
There is something deeply moving about watching hope take shape, not as a slogan or a speech, but as people coming together to build the cancer care Africa deserves. The African Organization for Research and Training in Cancer (AORTIC) 2025 Congress in Tunisia held in November was a vivid reminder...
ASTRO Marks Former President Biden’s Prostate Cancer Treatment Milestone
The American Society for Radiation Oncology (ASTRO) congratulates former President Joe Biden on completing his course of radiation therapy, which he marked by ringing the ceremonial bell alongside his radiation oncology care team. “President Biden’s bell-ringing milestone underscores the vital role ...
Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes
A new analysis spanning more than 3 decades of Eastern Cooperative Oncology Group and American College of Radiology Imaging Network (ECOG-ACRIN) clinical trial data demonstrates that Black patients with acute myeloid leukemia (AML) present with the disease at a significantly younger age and...
Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas
The addition of the PD-L1–targeting monoclonal antibody durvalumab to conventional perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in a statistically significant and clinically meaningful improvement in overall survival, with benefit seen...
Final Analysis Supports Use of Durvalumab Plus BCG Infusions in High-Risk Non–Muscle-Invasive Bladder Cancer
In patients with high-risk non–muscle-invasive bladder cancer, the addition of 1 year of the PD-L1 inhibitor durvalumab to standard induction and maintenance bacillus Calmette-Guérin (BCG) infusions led to a statistically significant and clinically meaningful improvement in disease-free survival...
